López-Guerra et al., 2020 - Google Patents
Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cellsLópez-Guerra et al., 2020
View HTML- Document ID
- 2877493544639475766
- Author
- López-Guerra M
- Xargay-Torrent S
- Fuentes P
- Roldán J
- González-Farré B
- Rosich L
- Silkenstedt E
- García-León M
- Lee-Vergés E
- Giménez N
- Giró A
- Aymerich M
- Villamor N
- Delgado J
- López-Guillermo A
- Puente X
- Campo E
- Toribio M
- Colomer D
- Publication year
- Publication venue
- Oncogene
External Links
Snippet
Targeting Notch signaling has emerged as a promising therapeutic strategy for chronic lymphocytic leukemia (CLL), particularly in NOTCH1-mutated patients. We provide first evidence that the Notch ligand DLL4 is a potent stimulator of Notch signaling in NOTCH1 …
- 206010008958 Chronic lymphocytic leukaemia 0 title abstract description 164
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| López-Guerra et al. | Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells | |
| Nishikawa et al. | Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression via CCR5 | |
| Tsuyada et al. | CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells | |
| Choi et al. | Tumour-vasculature development via endothelial-to-mesenchymal transition after radiotherapy controls CD44v6+ cancer cell and macrophage polarization | |
| Yumoto et al. | Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow | |
| Newman et al. | Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme | |
| Wang et al. | PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness | |
| Zhang et al. | Dedifferentiation process driven by radiotherapy-induced HMGB1/TLR2/YAP/HIF-1α signaling enhances pancreatic cancer stemness | |
| Nasser et al. | Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion | |
| Xing et al. | Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells | |
| Murayama et al. | Oncogenic fusion gene CD74-NRG1 confers cancer stem cell–like properties in lung cancer through a IGF2 autocrine/paracrine circuit | |
| Ma et al. | CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model | |
| Rogers et al. | Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology | |
| Takagi et al. | Platelets enhance multiple myeloma progression via IL-1β upregulation | |
| Wang et al. | Autocrine and paracrine chemokine receptor 7 activation in head and neck cancer: implications for therapy | |
| Larrue et al. | Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells | |
| Chen et al. | A NF-ĸB-Activin A signaling axis enhances prostate cancer metastasis | |
| Xu et al. | TEM8 marks neovasculogenic tumor-initiating cells in triple-negative breast cancer | |
| Yuan et al. | Endoplasmic reticulum stress promotes the release of exosomal PD-L1 from head and neck cancer cells and facilitates M2 macrophage polarization | |
| Mougiakakos et al. | The IKZF1–IRF4/IRF5 axis controls polarization of myeloma-associated macrophages | |
| Silkenstedt et al. | Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy | |
| Kiyohara et al. | EMP2 is a novel therapeutic target for endometrial cancer stem cells | |
| Azoitei et al. | Protein kinase D2 is a novel regulator of glioblastoma growth and tumor formation | |
| Turrell et al. | Age-associated microenvironmental changes highlight the role of PDGF-C in ER+ breast cancer metastatic relapse | |
| Zhou et al. | LIN28B activation by PRL-3 promotes Leukemogenesis and a stem cell–like transcriptional program in AML |